You are leaving

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

HARMONi Clinical Trial

Ivonescimab (SMT112/AK112)


HARMONi Phase 3 Clinical Trial

EGFR+ Advanced NSCLC Who Have Progressed After 3rd Generation EGFR-TKI (osimertinib)

NCT05184712: Click to view on


Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in Clinical Development in the U.S. & EU.*
Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.

Ivonescimab simultaneously engages both PD-1 & VEGF.
To-date 825+ patients have been treated with ivonescimab in clinical trials in China and Australia. Summit is actively recruiting 100+ patients in the U.S., Canada and Europe; the overall study will include over 400 patients worldwide.




  • Expected survival ≥3 months
  • Locally advanced (Stage IIIB/IIIC) or metastatic NSCLC that has progressed on 3rd generation EGFR-TKI (e.g., osimertinib)
  • At least 1 measurable noncerebral lesion
  • Adequate organ and hematologic function
  • Has not received other systemic antitumor therapy for the advanced stage (IIIB to IV) of NSCLC
  • Tumor does not surround important blood vessels, have obvious necrosis and/or cavitation or invade the surrounding vital organs and blood vessels
  • No symptomatic metastases of the central nervous system
  • No history of esophageal gastric varices, severe ulcers or wounds that do not heal
  • No history of severe bleeding tendencies or coagulopathy, or hemoptysis within last 4 weeks


For additional information on the HARMONi Clinical Trial, please contact


1. Manegold et al., (2016); JTO 12:2.194-207.; 2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.; 3. Tamura et al., (2020) Med Oncol 37:2, 10.1007.


Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).